These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20981086)

  • 1. Drug development: Longer-lived proteins.
    Hubbell JA
    Nature; 2010 Oct; 467(7319):1051-2. PubMed ID: 20981086
    [No Abstract]   [Full Text] [Related]  

  • 2. PharmGKB summary: peginterferon-α pathway.
    Shuldiner SR; Gong L; Muir AJ; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Sep; 25(9):465-74. PubMed ID: 26111151
    [No Abstract]   [Full Text] [Related]  

  • 3. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy.
    Hu J; Wang G; Zhao W; Gao W
    J Control Release; 2016 Sep; 237():71-7. PubMed ID: 27393654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
    Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM
    Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of pegylated proteins in oncology.
    Crawford J
    Cancer Treat Rev; 2002 Apr; 28 Suppl A():1-2. PubMed ID: 12173406
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pegylated interferons: preliminary review of their pharmacokinetic characteristics].
    Azanza Perea JR
    Rev Clin Esp; 2001 Apr; 201(4):205-12. PubMed ID: 11447908
    [No Abstract]   [Full Text] [Related]  

  • 8. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant protein hydrazides: application to site-specific protein PEGylation.
    Thom J; Anderson D; McGregor J; Cotton G
    Bioconjug Chem; 2011 Jun; 22(6):1017-20. PubMed ID: 21618993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
    Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
    Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific polymer modification of therapeutic proteins.
    Kochendoerfer GG
    Curr Opin Chem Biol; 2005 Dec; 9(6):555-60. PubMed ID: 16233987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylation: engineering improved pharmaceuticals for enhanced therapy.
    Molineux G
    Cancer Treat Rev; 2002 Apr; 28 Suppl A():13-6. PubMed ID: 12173407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon-alpha(2b) and ribavirin.
    Ahn J; Flamm S
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):17-25. PubMed ID: 15482168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.
    Costa MB; Picon PD; Sander GB; Cuni HN; Silva CV; Meireles RP; Góes ACMA; Batoreu NM; Maia MLS; Albuquerque EM; Matos DCS; Saura PL
    BMC Pharmacol Toxicol; 2018 Jan; 19(1):1. PubMed ID: 29301580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
    J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylation of interferon alfa: structural and pharmacokinetic properties.
    Pedder SC
    Semin Liver Dis; 2003; 23 Suppl 1():19-22. PubMed ID: 12934164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.